A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Topical Formulation with Cordia verbenacea Essential Oil and Glycolic Acid

This study evaluated the effect of Cordia verbenacea essential oil (CV) and glycolic acid 70 % (GA), isolated and associated, on Wistar rats back skin. A base gel was added to 2 % of CV and/or 10 % of GA, thus forming 4 formulations: 1) GA + CV, 2) CV, 3) GA, and 4) gel base. All formulation had their final pH adjusted to 3,5 and were applied once daily, for 15 consecutive days, on 4 areas with 1 cm(2), while another area without application (control). Statistical analysis of biopsies showed no difference in epidermis thickness and stratum corneum. Among fibroblast counts there was a statistical significance for groups exposed to the GA and to the association. Only in the group exposed to GAT there was significant difference in leukocytes number. The association of GA with CV proved favorable because it increased fibroblast counts without increasing leukocyte numbers, meaning inflammatory reaction may be reduced.2961004100

Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases

<p>Abstract</p> <p>Background</p> <p>In some clinical situations, for which RCT are rare or impossible, the majority of the evidence comes from observational studies, but standard estimations could be biased because they ignore covariates that confound treatment decisions and outcomes.</p> <p>Methods</p> <p>Three observational studies were conducted to assess the benefit of Allo-SCT in hematological malignancies of multiple myeloma, follicular lymphoma and Hodgkin’s disease. Two statistical analyses were performed: the propensity score (PS) matching approach and the inverse probability weighting (IPW) approach.</p> <p>Results</p> <p>Based on PS-matched samples, a survival benefit in MM patients treated by Allo-SCT, as compared to similar non-allo treated patients, was observed with an HR of death at 0.35 (95%CI: 0.14-0.88). Similar results were observed in HD, 0.23 (0.07-0.80) but not in FL, 1.28 (0.43-3.77). Estimated benefits of Allo-SCT for the original population using IPW were erased in HR for death at 0.72 (0.37-1.39) for MM patients, 0.60 (0.19-1.89) for HD patients, and 2.02 (0.88-4.66) for FL patients.</p> <p>Conclusion</p> <p>Differences in estimated benefits rely on whether the underlying population to which they apply is an ideal randomized experimental population (PS) or the original population (IPW). These useful methods should be employed when assessing the effects of innovative treatment in non-randomized experiments.</p